A PHASE 1 OPEN-LABEL STUDY OF PF-07934040 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE
Clinical Trial Grant
Awarded By
Pfizer, Inc.
Start Date
February 24, 2025
End Date
February 27, 2030
Awarded By
Pfizer, Inc.
Start Date
February 24, 2025
End Date
February 27, 2030